Top Big Data Companies With Best Stability & Growth (2,162)

Cost & Operational Efficiency: Disclosures indicate adjusted profitability metrics improved despite lower revenue, suggesting tighter cost control and mix shifts. Management highlights actions to reduce lower‑return spend and improve margins.

Product Line Growth: Owned properties like Startpage and MapQuest show rising engagement and property‑level revenue in recent periods. Company updates point to growth within the Products segment even as consolidated revenue fell.

Future-Ready Strategy: Leadership emphasizes integrating AI and machine learning into its RAMP platform to enhance efficiency and scalability. Recent commentary frames a strategic focus on AI‑driven optimization and product enhancements.

Strong Revenue Growth: Recent results show year-over-year increases in revenue and test volumes through 2025 and early 2026. Expanding U.S. adoption and rising Galleri volumes are cited as key contributors.

Strategic Partnerships: Announcements include Epic EHR integration to streamline ordering and results across many health systems, supporting broader access. International and channel collaborations, including Samsung-linked expansion plans, are positioned to extend reach.

Investor Backing & Capital Strength: Post–Illumina spin‑off funding and subsequent equity raises point to a multiyear cash runway. Additional financing provides flexibility to pursue regulatory, reimbursement, and commercialization goals.

Strong Revenue Growth: Recent results show net revenue increased 8.2% year over year in Q1 2026 and rose mid‑single digits in FY 2025, with organic growth remaining positive. Pricing and resilient demand in core categories supported the top line while volumes stabilize, with Emerging Markets contributing meaningfully.

Market Expansion: Emerging Markets were the standout growth engine in Q1 2026 and have offset softer trends in some developed regions. Expansion of distribution and category depth in faster‑growing geographies underpins ongoing exposure to higher‑growth markets.

Future-Ready Strategy: Management plans to improve volumes, step up brand investment, drive cost savings, and benefit from stabilizing cocoa costs to sustain profitable growth over multiple years. Long‑term targets and reiterated guidance signal continued reinvestment and operational initiatives to support durable performance.

Strong Revenue Growth: Multiple signals, including multi‑year FT1000 recognition, recent regional gains, and directionally consistent third‑party revenue scale estimates, indicate sustained expansion. Materials suggest growth continues even if the pace is more measured than earlier years.

Product Line Growth: The launch of a self‑serve platform (rtb.com) and continued moves beyond core enterprise retargeting broaden the offering and expand the addressable market. Evidence points to ongoing product expansion aimed at new customer segments.

Future-Ready Strategy: Active testing and implementation around Chrome’s Privacy Sandbox and participation in industry ecosystems (e.g., Prebid, IAB Tech Lab) show preparation for post‑third‑party‑cookie dynamics. This positioning is presented as a medium‑term growth enabler.

Strong Revenue Growth: Total sales increased from more than $41 billion in 2024 to more than $43 billion in 2025, and assets under management rose from $524 billion to $584 billion. Life insurance in force also expanded, indicating a larger book of business.

Profitability: Operating earnings reached a record near $3.9 billion in 2025 versus roughly $2.8 billion in 2024, supported by strong sales and favorable markets. Dividend capacity reached a company record for 2026, consistent with strong underlying earnings power.

Investor Backing & Capital Strength: Major agencies affirmed very strong financial strength ratings, and total adjusted capital remained elevated. The company approved its largest‑ever estimated dividend for 2026 and maintained a higher dividend interest rate.

Strong Revenue Growth: Reported revenue increased sharply in 2025 and continued to rise in Q1 2026, with management raising full‑year 2026 revenue guidance and signaling improved operating leverage.

Diversified Revenue Streams: Both Diagnostics and the higher‑margin Data & Applications businesses showed growth in recent updates, indicating multiple engines driving the top line.

Strategic Partnerships: The company expanded multi‑year collaborations with major pharmaceutical firms and highlighted a sizable pipeline and contract values that support future demand.

Strong Revenue Growth: Company communications report that ARR more than tripled in 2025 and describe “breakout momentum” supporting scale‑up. These disclosures also note expanded sponsor relationships alongside rising subscription and services revenue.

Market Expansion: Public materials outline added or relocated offices beyond Chicago (e.g., Dallas, New York, Toronto, Bengaluru), with third‑party listings reflecting multiple locations. A steady 2025–2026 update cadence on footprint suggests a broader go‑to‑market presence.

Product Line Growth: Announcements detail the Astradis analytics/AI platform and a new AI‑driven Pricing Suite, with additional industry‑specific capabilities introduced in 2026. Recent case studies for PE‑backed operators indicate continued investment and adoption across use cases.

Strong Revenue Growth: Recent quarterly results and a raised full‑year outlook indicate sustained top‑line expansion with momentum exceeding earlier expectations. Feedback suggests a growing demand pipeline and subscription strength are reinforcing this trajectory.

Healthy Cash Flow: Recent quarters delivered strong free cash flow alongside improved operating performance, signaling solid cash generation while scaling. This pattern points to better cash conversion even as the company continues to invest.

Innovation-Driven Growth: Ongoing AI‑related feature releases and partnerships (including vector search, embeddings, and LangChain) position the platform to capture emerging AI workloads. Management’s positioning of Atlas as a data layer for AI adds a secular growth catalyst.

Investor Backing & Capital Strength: A $372M Series D in June 2024 led by a16z with Sanofi participation provides substantial capital to expand the pipeline and AI capabilities. Reports characterize this as a material valuation step-up and part of a sizable overall funding base.

Strategic Partnerships: A first-of-its-kind AI collaboration with Sanofi and OpenAI and an out‑licensing deal of gusacitinib to Sanofi (up to €545M) indicate strong external validation and access to enterprise-scale deployment. These alliances reinforce market credibility while opening channels for co-development and monetization.

Product Line Growth: Ongoing in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor and an anti‑CD226 program) and 2026 updates showing rapid Phase 1 initiation suggest a broadening and advancing portfolio. The rebrand and model shift aim to support a faster-moving, diversified pipeline across immunology and related areas.

Strong Revenue Growth: Company disclosures describe year-over-year revenue and ARR gains through 2023–2024, highlighted by a record FY2024 and rising capacity under management. Feedback suggests new customer bookings and overall customer count expanded entering 2024 and continued through 2026.

Profitability: The business reported remaining profitable in FY2024 while scaling operations. Feedback suggests this profitability accompanied growth in customers, capacity under management, and deal sizes.

Investor Backing & Capital Strength: A majority/strategic growth investment led by Vista Equity Partners signaled substantial external confidence and scale. Additional backing from firms such as TCV and KKR further supports access to capital for product and go‑to‑market expansion.

Profitability: Recent quarters show rising gross profit and expanded non‑GAAP margins, with GAAP profitability achieved in late 2025 and adjusted EBITDA progressing after a solid start to 2026. Feedback suggests operating leverage is improving as the company scales.

Healthy Cash Flow: Free cash flow increased meaningfully in early 2026, and the company reports a sizable cash balance with no debt. These indicators point to improved financial flexibility to support growth and execution.

Product Line Growth: Newer offerings (e.g., Dispute Resolve, ACH risk, broader abuse coverage) are gaining adoption, with more merchants using multiple products. Partnerships and integrations are broadening distribution and reinforcing multi‑product traction.

Strong Market Position & Advantage: Independent market‑share analysis places the company as the top vendor in a fast‑growing process mining category, indicating outperformance as the market expands. Repeated leader placements in major analyst evaluations reinforce sustained competitive advantage.

Strategic Partnerships: An expanded collaboration with a major hyperscaler (including deeper data integrations) signals stronger routes to market and tighter alignment with enterprise data platforms. Additional alliances across the ecosystem point to broader distribution and solution fit.

Innovation-Driven Growth: Ongoing platform launches oriented to AI and a broader process intelligence roadmap, alongside targeted acquisitions, extend the product’s scope and use cases. Reported customer value realized on the platform indicates innovations are translating into measurable outcomes.

Investor Backing & Capital Strength: A sizable Series D in May 2025 led by Goldman Sachs Alternatives and Smith Point Capital signals strong capital support to scale the platform. The oversubscribed round indicates momentum and runway for continued expansion.

Strategic Partnerships: Public launches with Nationwide and Transamerica put Bestow’s technology live in market, including instant‑decision products cited by partners and trade coverage. Named blue‑chip customers and the company’s 2025 recap highlight expanding enterprise adoption.

Strong Revenue Growth: Management reports indicate ARR expanded sharply in 2024 and over the prior two years following the pivot to enterprise software. These claims, reiterated in press and media coverage, point to accelerating top‑line momentum.

Investor Backing & Capital Strength: Recent financing events indicate robust external support, with Blackstone Growth leading a $100M minority round and company materials confirming the deal. Bloomberg’s valuation context and CB Insights’ listing align to show strong capital access and investor confidence.

Strong Hiring & Retention: Company updates highlight headcount growth beyond 200 in 2025, continued recognition on Built In’s 2026 Best Places to Work, and active senior hiring into 2025–2026. These signals align with a scaling organization expanding leadership and specialist roles.

Market Expansion: Public materials emphasize an expanded enterprise footprint into Fortune 100 use cases across public affairs, investor relations, and B2B marketing compared with earlier advocacy roots. Built In and company profiles describe a growth-stage posture with ongoing recruiting to support these markets.

Profitability: Q1 2026 returned to GAAP profitability with net income of $4.4M versus a loss a year earlier. Adjusted EBITDA grew 16% and the full‑year 2026 margin target was raised to at least 35.5%.

Resilient & Sustainable Growth: Contribution ex‑TAC rose 10% year over year in Q1 2026 and management reaffirmed at least low‑double‑digit ex‑TAC growth for 2026. CTV’s rapid expansion remains the primary engine of the company’s trajectory.

Healthy Cash Flow: Management guided to mid‑30% free‑cash‑flow growth for 2026, signaling improving cash generation alongside margin expansion. This points to operating leverage supporting stronger cash conversion.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3B valuation and a subsequent $750M debt package indicate strong capital support and investor confidence. These transactions suggest access to financing at scale to fund continued expansion.

Market Expansion: Company materials point to growth from more than 1,200 to 1,500+ customers and coverage of tens of millions of employees, alongside pushes into public sector and new geographies. New and deepened partnerships broaden routes to market and support footprint growth.

Product Line Growth: The acquisition of AppLearn added digital adoption capabilities, extending the DEX platform’s breadth for cross‑sell and upsell. Ongoing product releases (e.g., Infinity, Spark) reflect a widening portfolio aligned to category demand.

Strong Revenue Growth: Recent disclosures point to sharp year-over-year expansion with a multi‑quarter streak of growth into early 2026; feedback suggests momentum remained strong around the IPO timing.

Investor Backing & Capital Strength: An above‑range IPO with significant proceeds and a subsequent credit upgrade indicate healthy investor demand; feedback suggests backing from established sponsors and a 2025 minority investment further reinforce capital flexibility.

Innovation-Driven Growth: Enhancements to its AI platform (Cortex) and launches such as AppRefinery are credited with performance gains and wider adoption; feedback suggests ongoing product velocity supports continued expansion across the app economy.

Strong Revenue Growth: Recent results show revenue increased year over year through 2025 and into Q1 2026, with management raising full‑year 2026 guidance after exceeding the high end of its Q1 outlook. This points to continued momentum if forthcoming quarters meet targets.

Profitability: The company returned to GAAP profitability in 2025 and reported net income again in Q1 2026 alongside strong operating cash generation. Management’s share repurchases further indicate confidence in ongoing earnings and cash flow.

Strategic Partnerships: A long‑term, exclusive Yahoo agreement materially expands distribution, complemented by newer initiatives across Microsoft display inventory and CTV with Paramount and LG. These partnerships broaden reach and demand beyond legacy native placements.

Market Expansion: Multiple drugmakers have recently shifted contract‑pharmacy data/designation workflows to Truzo (e.g., Organon effective May 1, 2026; Gilead July 7, 2026; Alkermes December 1, 2025), signaling expanding platform uptake. Industry commentary in early 2026 also framed Kalderos/Truzo as a viable path amid 340B uncertainty, reinforcing active market presence.

Investor Backing & Capital Strength: A new funding round on January 3, 2025 and cumulative capital raised across multiple rounds indicate solid financial support to scale go‑to‑market and product. The June 17, 2026 acquisition by Model N further demonstrates external conviction in Kalderos’ strategic value.

Strategic Partnerships: Model N’s acquisition integrates Kalderos’ 340B and GTN capabilities into a broader life‑sciences revenue platform, providing access to established distribution channels. Notices and industry records highlight collaboration with major manufacturers, reflecting deepening commercial ties.

Strong Revenue Growth: Recent quarters show revenue and GMV rising at strong double‑digit rates, with management citing a long streak of elevated GMV growth and issuing guidance that implies continued expansion.

Profitability: The latest quarter delivered positive GAAP net income and a higher operating margin year over year, supported by improving unit economics and lower average funding costs.

Product Line Growth: Direct‑to‑consumer offerings are scaling quickly, led by rapid Affirm Card adoption and rising transactions per active consumer, broadening contribution beyond traditional checkout BNPL.